(in accordance with Regulation (EU) 2020/878)

M0024010-BRIMONIDINE TRATRATE



Version 1 Date of compilation: 22/11/2018 Version 5 (replaces version 4) Revision date

Revision date: 06/10/2023

Page 1 of 9 Print date: 28/06/2024

SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING.

1.1 Product identifier.

Product Name:BRIMONIDINE TRATRATEProduct Code:M0024010Chemical Name:5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine 2,3-dihydroxysuccinate (1:1)CAS No:70359-46-5

1.2 Relevant identified uses of the substance or mixture and uses advised against.

Raw material for master formulation

Uses advised against:

Uses other than those recommended.

1.3 Details of the supplier of the safety data sheet.

Company:	ACOFARMA DISTRIBUCIÓN S.A.
Address:	C/ Llobregat, 20, Pol. Ind. Santa Margarita
City:	Terrassa
Province:	Barcelona
Telephone:	902362203
Fax:	937360090
E-mail:	atencioncliente@acofarma.com
Web:	www.acofarma.es

1.4 Emergency telephone number: 902362203 (Only available during office hours; Monday-Friday; 09:00-18:00)

SECTION 2: HAZARDS IDENTIFICATION.

2.1 Classification of the substance or mixture.

In accordance with Regulation (EC) No 1272/2008: Acute Tox. 3 : Toxic if swallowed. Eye Irrit. 2 : Causes serious eye irritation. STOT SE 3 : May cause respiratory irritation. Skin Irrit. 2 : Causes skin irritation.

2.2 Label elements.

Labelling in accordance with Regulation (EC) No 1272/2008: Pictograms:



Signal Word:

Danger

Hazard statements:

- H301 Toxic if swallowed.
- H315 Causes skin irritation.
- H319 Causes serious eye irritation.
- H335 May cause respiratory irritation.

Precautionary statements:

P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P280	Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/
P301+P310	IF SWALLOWED: Immediately call a POISON CENTER/doctor/
P264	Wash thoroughly after handling.

(in accordance with Regulation (EU) 2020/878)

M0024010-BRIMONIDINE TRATRATE



Version 1Date of compilation: 22/11/2018Version 5 (replaces version 4)Revision date: 06/10/2023

Page 2 of 9 Print date: 28/06/2024

P301+P312	IF SWALLOWED: Call a POISON CENTER/doctor/ if you feel unwell
P312	Call a POISON CENTER/doctor/ if you feel unwell.
P337+P313	If eye irritation persists: Get medical advice/attention.

2.3 Other hazards.

The substance is not PBT The substance is not vPvB Substance does not have endocrine disrupting properties.

In normal use conditions and in its original form, the product itself does not involve any other risk for health and the environment.

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS.

3.1 Substances.

Mono-constituent.

Identifiers	Name	Concentrate	(*)Classification - Regulation (EC) No 1272/2008	
			Classification	Specifics concentration limits and Acute toxicity estimate
CAS No: 70359-46-5	5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6- quinoxalinamine 2,3-dihydroxysuccinate (1:1)	33 - 100 %	Acute Tox. 3, H301 - Eye Irrit. 2, H319 - STOT SE 3, H335 - Skin Irrit. 2, H315	-

			(*)Classification - Regulation (EC) No 1272/2008	
Identifiers	Name	Concentrate	Classification	Specifics concentration limits and Acute toxicity estimate
CAS No: 70359-46-5	5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6- quinoxalinamine 2,3-dihydroxysuccinate (1:1)	33 - 100 %	Acute Tox. 3, H301 - Eye Irrit. 2, H319 - STOT SE 3, H335 - Skin Irrit. 2, H315	-

(*) The complete text of the H phrases is given in section 16 of this Safety Data Sheet.

3.2 Mixtures.

Not applicable.

SECTION 4: FIRST AID MEASURES.

IRRITANT MIXTURE. Its repeated or prolonged contact with the skin or mucous membranes can cause irritant symptoms such as reddening of the skin, blisters, or dermatitis. Some of the symptoms may not be immediate. They can cause allergic reactions on the skin.

4.1 Description of first aid measures.

Immediate medical attention is required. Delayed effects may occur after the exposure to the product.

Inhalation.

Take the victim into open air; keep them warm and calm. If breathing is irregular or stops, perform artificial respiration. Do not administer anything orally. If unconscious, place them in a suitable position and seek medical assistance.

Eve contact.

Remove contact lenses, if present and if it is easy to do. Wash eyes with plenty of clean and cool water for at least 10 minutes while pulling eyelids up, and seek medical assistance. Dont let the person to rub the affected eye.

Skin contact.

Remove contaminated clothing. Wash skin vigorously with water and soap or a suitable skin cleaner. NEVER use solvents or thinners.

(in accordance with Regulation (EU) 2020/878)

M0024010-BRIMONIDINE TRATRATE

Version 1 Date of compilation: 22/11/2018

Version 5 (replaces version 4) Revision date: 06/10/2023

Page 3 of 9 Print date: 28/06/2024

🙏 acofarma

Ingestion.

If accidentally ingested, seek immediate medical attention. Keep calm. NEVER induce vomiting. The use of personal protective equipment is recommended for people providing first aid (see section 8).

4.2 Most important symptoms and effects, both acute and delayed.

Irritant Product, repeated or prolonged contact with skin or mucous membranes can cause redness, blisters or dermatitis, inhalation of spray mist or particles in suspension may cause irritation of the respiratory tract, some symptoms may not be immediate.

Toxic Product, accidental contact may result in serious respiratory difficulties, alteration of the central nervous system and in extreme cases, unconsciousness. Immediate medical assistance is required.

4.3 Indication of any immediate medical attention and special treatment needed.

Request immediate medical attention. Never administer anything orally to persons who are unconscious. Do not induce vomiting. If the person vomits, clear the respiratory tract. Keep the person comfortable. Turn him/her over to the left side and stay there while waiting for medical care.

SECTION 5: FIREFIGHTING MEASURES.

The product is NOT classified as flammable, in case of fire the following measures should be taken:

5.1 Extinguishing media.

Suitable extinguishing media:

Extinguisher powder or CO2. In case of more serious fires, also alcohol-resistant foam and water spray.

Unsuitable extinguishing media:

Do not use a direct stream of water to extinguish. In the presence of electrical voltage, you cannot use water or foam as extinguishing media.

5.2 Special hazards arising from the substance or mixture.

Special risks.

Exposure to combustion or decomposition products can be harmful to your health.

During a fire and depending on its magnitude the following may occur: - Toxic vapors or gases.

5.3 Advice for firefighters.

Use water to cool tanks, cisterns, or containers close to the heat source or fire. Take wind direction into account. Prevent the products used to fight the fire from going into drains, sewers, or waterways.

Fire protection equipment.

According to the size of the fire, it may be necessary to use protective suits against the heat, individual breathing equipment, gloves, protective goggles or facemasks, and boots. During extinction and depending on the magnitude and proximity to the fire, additional protective equipment such as chemical protection gloves, heat-reflecting suits or gas-tight suits may be required.

SECTION 6: ACCIDENTAL RELEASE MEASURES.

6.1 Personal precautions, protective equipment and emergency procedures.

For exposure control and individual protection measures, see section 8.

6.2 Environmental precautions.

Product not classified as hazardous for the environment, avoid spillage as much as possible.

6.3 Methods and material for containment and cleaning up.

Contain and collect spillage with inert absorbent material (earth, sand, vermiculite, Kieselguhr...) and clean the area immediately with a suitable decontaminant.

Deposit waste in closed and suitable containers for disposal, in compliance with local and national regulations (see section 13).

6.4 Reference to other sections.

For exposure control and individual protection measures, see section 8.

For later elimination of waste, follow the recommendations under section 13.

(in accordance with Regulation (EU) 2020/878)

M0024010-BRIMONIDINE TRATRATE

Version 1 Date of compilation: 22/11/2018

Version 5 (replaces version 4) Revision date: 06/10/2023

Page 4 of 9 Print date: 28/06/2024

Å acofarma

SECTION 7: HANDLING AND STORAGE.

7.1 Precautions for safe handling.

For personal protection, see section 8.

In the application area, smoking, eating, and drinking must be prohibited.

Follow legislation on occupational health and safety.

Never use pressure to empty the containers. They are not pressure-resistant containers. Keep the product in containers made of a material identical to the original.

7.2 Conditions for safe storage, including any incompatibilities.

Store according to local legislation. Observe indications on the label. Store the containers between 15 and 25 ° C, in a dry and well-ventilated place, far from sources of heat and direct solar light. Keep far away from ignition points. Keep away from oxidising agents and from highly acidic or alkaline materials. Do not smoke. Prevent the entry of non-authorised persons. Once the containers are open, they must be carefully closed and placed vertically to prevent spills.

The product is not affected by Directive 2012/18/EU (SEVESO III).

7.3 Specific end use(s).

No additional information available

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION.

8.1 Control parameters.

The product does NOT contain substances with Professional Exposure Environmental Limit Values. The product does NOT contain substances with Biological Limit Values.

8.2 Exposure controls.

Measures of a technical nature:

Provide adequate ventilation, which can be achieved by using good local exhaust-ventilation and a good general exhaust system.

Concentration:	100 %		
Uses:	Raw material for master formulation		
Breathing protect	tion:		
PPE:	Particle filter mask		
Characteristics:	«CE» marking, category III. Made of filtering material, it covers nose, mouth and chin.		
CEN standards:	EN 149		
Maintenance:	Check for any tears, defects, etc. before use. Since it is disposable individual protection equipment, it should be replaced after use.		
Observations:	Does not protect worker unless properly adjusted. Follow the manufacturer's instructions regarding suitable use of the equipment.		
Filter Type needed:	P2		
Hand protection:			
PPE:	Non-disposable protective gloves against chemicals.		
Characteristics:	«CE» marking, category III. Check the list of chemicals for which the glove has been tested.		
CEN standards:	EN 374-1, En 374-2, EN 374-3, EN 420		
Maintenance:	A schedule for the periodical replacement of gloves should be established in order to guarantee their replacement before pollutants permeate them. The use of contaminated gloves could be more dangerous than not using gloves, since the pollutant can gradually accumulate in the glove's material.		
Observations:	They are to be replaced whenever tears, cracks or deformations are observed or when exterior dirt could reduce their strength.		
Material:	PVC (polyvinyl chloride)Breakthrough time (min.):> 480Material thickness (mm):0,35		
Eye protection:			
PPE: Characteristics:	Protective goggles against particle impacts. «CE» marking, category II. Eye protector against dust and smoke.		
CEN standards:	EN 165, EN 166, EN 167, EN 168		
Maintenance:	Visibility through lenses should be ideal. Therefore, these parts should be cleaned daily. Protectors should be disinfected periodically following the manufacturer's instructions.		

(in accordance with Regulation (EU) 2020/878)

M0024010-BRIMONIDINE TRATRATE

Version 1 Date of compilation: 22/11/2018 Version 5 (replaces version 4) Revision date: 06/10/2023 Page 5 of 9 Print date: 28/06/2024

🙏 acofarma

Observations:	Some signs of wear and tear include: yellow colouring of the lenses, superficial scratching of the lenses, scraping etc.
Skin protection:	
PPE:	Chemical protective clothing
Characteristics:	«CE» marking, category III. Clothing should fit properly. The level of protection must be set according to a test parameter called BT (Breakthrough Time), which indicates how long it takes for the chemical to pass through the material.
CEN standards:	EN 464,EN 340, EN 943-1, EN 943-2, EN ISO 6529, EN ISO 6530, EN 13034
Maintenance:	In order to guarantee uniform protection, follow the washing and maintenance instructions provided by the manufacturer.
Observations:	The protective clothing's design should facilitate correct positioning, staying in place without moving for the period of use expected, bearing in mind environmental factors as well as any movement or position the user might adopt while carrying out the activity.
PPE:	Anti-static safety footwear against chemicals.
Characteristics:	«CE» marking, category III. Check the list of chemicals against which the footwear is resistant.
CEN standards:	EN ISO 13287, EN 13832-1, EN 13832-2, EN 13832-3, EN ISO 20344, EN ISO 20345
Maintenance:	For correct maintenance of this kind of safety footwear, it is necessary to observe the instructions specified by the manufacturer. The footwear should be replaced as soon as any sign of damage is observed.
Observations:	The footwear should be cleaned regularly and dried when damp, although it should not be placed too close to a source of heat in order to avoid any sharp changes in temperature.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES.

9.1 Information on basic physical and chemical properties.

Physical state: Solid - Dust Colour: off-white / slightly yellow Odour: No data available Odour threshold: Not applicable Melting point: 207.5 °C Freezing point: Not available Boiling point or initial boiling point and boiling range: Not available Flammability: non-flammable Lower explosion limit: Not available Upper explosion limit: Not available Flash point: Not available Auto-ignition temperature: Not available Decomposition temperature: Not available pH: No data available Kinematic viscosity: Not applicable Solubility: Insoluble in methanol Hydrosolubility: Soluble in water Liposolubility: Not available Partition coefficient n-octanol/water (log value): Not available Vapour pressure: Not available Absolute density: Not available Relative density: Not available Relative vapour density: Not applicable Particle characteristics: Not available

9.2 Other information

Not applicable/Not available due to the nature/properties of the product

SECTION 10: STABILITY AND REACTIVITY.

10.1 Reactivity.

The product does not present hazards by their reactivity.

10.2 Chemical stability.

Stable under the recommended handling and storage conditions (see section 7).

(in accordance with Regulation (EU) 2020/878)

M0024010-BRIMONIDINE TRATRATE

Version 1 Date of compilation: 22/11/2018

Version 5 (replaces version 4) Revision date: 06/10/2023

Page 6 of 9 Print date: 28/06/2024

Å acofarma

10.3 Possibility of hazardous reactions.

The product does not present possibility of hazardous reactions.

10.4 Conditions to avoid.

Avoid any improper handling.

10.5 Incompatible materials.

Keep away from oxidising agents and from highly alkaline or acidic materials in order to prevent exothermic reactions.

10.6 Hazardous decomposition products.

No decomposition if used for the intended uses.

SECTION 11: TOXICOLOGICAL INFORMATION.

IRRITANT MIXTURE. Splashes in the eyes can cause irritation.

IRRITANT MIXTURE. The inhalation of spray mist or suspended particulates can irritate the respiratory tract. It can also cause serious respiratory difficulties, central nervous system disorders, and in extreme cases, unconsciousness.

IRRITANT MIXTURE. Its repeated or prolonged contact with the skin or mucous membranes can cause irritant symptoms such as reddening of the skin, blisters, or dermatitis. Some of the symptoms may not be immediate. They can cause allergic reactions on the skin.

11.1 Information on hazard classes as defined in Regulation (EC) Nº 1272/2008.

There are no tested data available on the product.

Repeated or prolonged contact with the product can cause the elimination of oil from the skin, giving rise to non-allergic contact dermatitis and absorption of the product through the skin.

a) acute toxicity; Product classified: Acute toxicity (Oral), Category 3: Toxic if swallowed.

Acute Toxicity Estimate (ATE): Substances: ATE (Oral) = 100 mg/kg

b) skin corrosion/irritation;Product classified:Skin irritant, Category 2: Causes skin irritation.

c) serious eye damage/irritation; Product classified: Eye irritation, Category 2: Causes serious eye irritation.

d) respiratory or skin sensitisation; Not conclusive data for classification.

e) germ cell mutagenicity; Not conclusive data for classification.

f) carcinogenicity; Not conclusive data for classification.

g) reproductive toxicity; Not conclusive data for classification.

h) STOT-single exposure;Product classified:Specific target organ toxicity following a single exposure, Category 3: May cause respiratory irritation.

i) STOT-repeated exposure; Not conclusive data for classification.

j) aspiration hazard; Not conclusive data for classification.

11.2 Information on other hazards. Endocrine disrupting properties

(in accordance with Regulation (EU) 2020/878)

M0024010-BRIMONIDINE TRATRATE

Å acofarma

Version 1 Date of compilation: 22/11/2018

Version 5 (replaces version 4)

Revision date: 06/10/2023

Page 7 of 9 Print date: 28/06/2024

This product does not contain components with endocrine-disrupting properties with effects on human health.

Other information

There is no information available on other adverse health effects.

SECTION 12: ECOLOGICAL INFORMATION.

12.1 Toxicity.

No information is available regarding the ecotoxicity.

12.2 Persistence and degradability.

No information is available regarding the biodegradability No information is available on the degradability No information is available about persistence and degradability of the product.

12.3 Bioaccumulative potential.

No information is available regarding the bioaccumulation.

12.4 Mobility in soil.

No information is available about the mobility in soil. The product must not be allowed to go into sewers or waterways. Prevent penetration into the ground.

12.5 Results of PBT and vPvB assessment.

No information is available about the results of PBT and vPvB assessment of the product.

12.6 Endocrine disrupting properties.

This product doesn't contain components with environmental endocrine disrupting properties.

12.7 Other adverse effects.

The product is not affected by the Regulation (EC) No 1005/2009 of the European Parliament and of the Council of 16 September 2009 on substances that deplete the ozone layer.

No information is available about other adverse effects for the environment.

SECTION 13: DISPOSAL CONSIDERATIONS.

13.1 Waste treatment methods.

Do not dump into sewers or waterways. Waste and empty containers must be handled and eliminated according to current, local/national legislation.

Follow the provisions of Directive 2008/98/EC regarding waste management.

SECTION 14: TRANSPORT INFORMATION.

Transportation is not dangerous. In case of road accident causing the product's spillage, proceed in accordance with point 6.

14.1 UN number or ID number.

Transportation is not dangerous.

14.2 UN proper shipping name.

Description: ADR/RID: Not classified as hazardous for transport. IMDG: Not classified as hazardous for transport. ICAO/IATA: Not classified as hazardous for transport.

14.3 Transport hazard class(es).

Transportation is not dangerous.

14.4 Packing group.

Transportation is not dangerous.

(in accordance with Regulation (EU) 2020/878)

M0024010-BRIMONIDINE TRATRATE

Version 1 Date of compilation: 22/11/2018

Version 5 (replaces version 4) Revision date: 06/10/2023

Page 8 of 9 Print date: 28/06/2024

🙏 acofarma

14.5 Environmental hazards.

Transportation is not dangerous. Transport by ship, FEm – Emergency sheets (F – Fire, S - Spills): Not applicable.

14.6 Special precautions for user.

Transportation is not dangerous.

14.7 Maritime transport in bulk according to IMO instruments.

Not classified as hazardous for transport.

SECTION 15: REGULATORY INFORMATION.

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture.

The product is not affected by Regulation (EU) No 528/2012 concerning the making available on the market and use of biocidal products.

The product is not affected by the procedure established Regulation (EU) No 649/2012, concerning the export and import of dangerous chemicals.

15.2 Chemical safety assessment.

No Chemical Safety Assessment has been carried out for this substance/mixture by the supplier.

SECTION 16: OTHER INFORMATION.

Complete text of the H phrases that appear in section 3:

H301	Toxic if swallowed.
H315	Causes skin irritation.
H319	Causes serious eye irritation.
H335	May cause respiratory irritation.

Classification codes:

Acute Tox. 3 : Acute toxicity (Oral), Category 3 Eye Irrit. 2 : Eye irritation, Category 2 STOT SE 3 : Specific target organ toxicity following a single exposure, Category 3 Skin Irrit. 2 : Skin irritant, Category 2

Changes regarding to the previous version:

- Change in the hazard classification (SECTION 2.1).
- Changes in the composition of the product (SECTION 3.2).
- Modification of the symptoms (SECTION 4.2).
- Modifications in the handling and storage precautions (SECTION 7.1).
- Modifications in the handling and storage precautions (SECTION 7.2).
- Change of the uses of the product (SECTION 7.3).
- Modification in the values of the physical and chemical properties (SECTION 9).
- Change in the hazard classification (SECTION 11.1).

Classification and procedure used to derive the classification for mixtures according to Regulation (EC) 1272/2008 [CLP]:Physical hazardsOn basis of test dataHealth hazardsCalculation methodEnvironmental hazardsCalculation method

It is advisable to carry out basic training with regard to health and safety at work in order to handle this product correctly.

(in accordance with Regulation (EU) 2020/878)

🙏 acofarma

M0024010-BRIMONIDINE TRATRATE

Version 1 Date of compilation: 22/11/2018 Version 5 (replaces version 4) Revision date: 06/10/2023 Page 9 of 9 Print date: 28/06/2024

Abbreviations and acronyms used: CEN: European Committee for Standardization.

PPE: Personal protection equipment.

Key literature references and sources for data: http://eur-lex.europa.eu/homepage.html http://echa.europa.eu/ Regulation (EU) 2020/878. Regulation (EC) No 1907/2006. Regulation (EC) No 1272/2008.

The information given in this Safety Data Sheet has been drafted in accordance with COMMISSION REGULATION (EU) 2020/878 of 18 June 2020 amending Annex II to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemical substances and mixtures (REACH).

The information in this Safety Data Sheet on the Preparation is based on current knowledge and on current EC and national laws, as far as the working conditions of the users is beyond our knowledge and control. The product must not be used for purposes other than those that are specified without first having written instructions on how to handle. It is always the responsibility of the user to take the appropriate measures in order to comply with the requirements established by current legislation. The information contained in this Safety Sheet only states a description of the safety requirements for the preparation, and it must not be considered as a guarantee of its properties.